bendamustine hydrochloride has been researched along with Diffuse Large B-Cell Lymphoma in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.08) | 29.6817 |
| 2010's | 22 (45.83) | 24.3611 |
| 2020's | 25 (52.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YW; Cheng, CL; Chou, WC; Hong, RL; Hou, HA; Huang, TC; Ko, BS; Kuo, SH; Lin, CC; Lin, YC; Liu, JH; Lo, MY; Lu, LC; Tien, FM; Tsai, XC; Wang, YW; Wu, SJ; Yao, M | 1 |
| Abraham, I; Calamia, M; McBride, A | 1 |
| Croft, B; Herrera, AF; Jiang, Y; Lovejoy, AF; Musick, L; Opat, S; Paulson, JN; Ray, J; Sehn, LH; Tracy, S | 1 |
| Harada, N; Hino, M; Koh, H; Kuno, M; Makuuchi, Y; Nakamae, H; Nakashima, Y; Nishimoto, M; Okamura, H; Okayama, Y; Takakuwa, T | 1 |
| Kong, FC; Li, F; Wang, SX; Yu, M; Zhou, YL | 1 |
| Ayers, A; Crombie, JL; Feng, L; Gouni, S; Hess, B; Ip, A; Iqbal, M; Kamdar, MK; Khurana, A; Lin, Y; Merryman, RW; Neelapu, SS; Rosenthal, AC; Strati, P; Watson, G | 1 |
| Ambarkhane, S; Cordoba, R; Kapetanakis, V; Prawitz, T; Sabatelli, L; Sharma, A; Westley, T | 1 |
| Belada, D; Benesova, K; Duras, J; Hanackova, V; Janikova, A; Karban, J; Mocikova, H; Obr, A; Prochazka, V; Steinerova, K; Sykorova, A; Trneny, M; Vodicka, P | 1 |
| Ambarkhane, S; Fleury, I; Greil, R; Hess, G; Huang, D; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Salles, G; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL | 1 |
| Ballard, HJ; Barta, SK; Chen, AI; Chong, EA; Garfall, A; Gerson, JN; Ghilardi, G; Gier, S; Hodges Dwinal, A; Jäger, U; Landsburg, JD; Maziarz, RT; Myers, J; Napier, E; Nasta, SD; Pajarillo, R; Porter, DL; Ruella, M; Schachter, L; Schuster, SJ; Svoboda, J; Victoriano, D; Weber, E; Williamson, S; Wohlfarth, P; Yelton, R | 1 |
| Kawasaki, N; Nishito, Y; Yoshimura, Y; Yoshiura, S | 1 |
| Bertoni, F; Tarantelli, C | 1 |
| Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U | 1 |
| Aisa, Y; Ito, C; Kadota, S; Kurosawa, S; Nakayama, H; Nakazato, T; Okubo, S; Sakurai, A; Shinmura, K | 1 |
| Andreadis, C; Banerjee, R; Beitinjaneh, AM; Dahiya, S; Deol, A; Dorritie, KA; Frank, MJ; Ghobadi, A; Goy, A; Hill, BT; Jacobs, MT; Jain, MD; Jain, P; Lekakis, L; Lin, Y; Locke, FL; Maurer, MJ; Mcguirk, JP; Miklos, DB; Munoz, JL; Neelapu, SS; Oluwole, OO; Paludo, J; Rapoport, AP; Shah, B; Vose, JM; Wang, ML; Wang, T; Wang, Y | 1 |
| Fujioka, Y; Matsuda, K; Okuda, S; Sugimoto, K | 1 |
| Ishio, T; Izumiyama, K; Kobayashi, M; Kondo, T; Mori, A; Morioka, M; Muraki, H; Saito, M; Tsukamoto, S; Yokoyama, E | 1 |
| Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL | 1 |
| Kodama, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Urabe, S; Uraisami, K; Wada, J | 1 |
| Doki, N; Haraguchi, K; Hayashi, Y; Ishimine, K; Kanemasa, Y; Kobayashi, T; Mino, M; Morita, Y; Najima, Y; Nakamura, S; Ohashi, K; Ohigashi, A; Okuya, T; Okuyama, Y; Sasaki, Y; Shimizu, H; Shimizuguchi, T; Shimoyama, T; Shingai, N; Tamura, T; Toya, T; Yagi, Y | 1 |
| Jakobs, F; Kron, F; Kurte, MS; Reinhardt, HC; Siefen, AC; von Tresckow, B | 1 |
| Assouline, S; Cheng, J; Flowers, CR; Herrera, AF; Hertzberg, M; Hirata, J; Kamdar, MK; Kim, TM; Kim, WS; Ku, G; Matasar, MJ; McMillan, A; Ozcan, M; Paulson, JN; Penuel, E; Sehn, LH | 1 |
| Eberhardt, J; Fischer, T; Jentsch-Ullrich, K; Kahl, C; Mohren, M; Schalk, E; Zeremski, V | 1 |
| Hamada, T; Hatta, Y; Iriyama, N; Koike, T; Miura, K; Nakagawa, M; Nakayama, T; Takahashi, H; Takei, M; Uchino, Y | 1 |
| Bergamaschini, L; Castelli, R; Deliliers, GL; Gidaro, A | 1 |
| Cheson, BD; Nowakowski, G; Salles, G | 1 |
| Cheng, CL; Chou, SC; Liu, JH; Tang, JL; Tien, HF; Yao, M | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Madhyastha, SP; Sharma, S; Singh, A; Udupa, K | 1 |
| Carli, G; D'Amore, ESG; Di Bona, E; Famengo, B; Paolini, R; Perbellini, O; Piazza, F; Ravelli, E; Ruggeri, M; Sartori, R; Tecchio, C; Tisi, MC; Visco, C | 1 |
| Berdeja, JG; Daniel, DB; Erter, J; Flinn, IW; Mace, JR | 1 |
| Ando, K; Chae, YS; Eom, HS; Kim, SJ; Kim, WS; Niitsu, N; Ogura, M; Ohmachi, K; Suh, C; Takahashi, N; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K; Uchida, T; Uike, N | 1 |
| de Fabritiis, P; Fratoni, S; Giovannini, M; Niscola, P; Palombi, M; Perrotti, A; Scaramucci, L; Tendas, A; Trawinska, MM | 1 |
| Acs, PI; Lee, P; Lynam, E; Rosen, PJ; Tabbara, IA; Vacirca, JL | 1 |
| Amino, N; Kaneko, N; Kita, A; Kuromitsu, S; Mitsuoka, K; Miyoshi, S; Mori, M; Yamanaka, K | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Gaudio, F; Guarini, A; Melpignano, A; Merchionne, F; Minoia, C; Pavone, V; Quarta, G; Quintana, G; Specchia, G | 1 |
| Ando, K; Kim, WS; Niitsu, N; Ogura, M; Suh, C; Tateishi, U; Tatsumi, M; Terauchi, T; Tobinai, K | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Bellosillo, B; Besses, C; Camacho, L; Fernández-Rodríguez, C; Ferraro, M; Gimeno, E; Navarro, A; Pairet, S; Salar, A; Sanchez-Gonzalez, B; Serrano, S | 1 |
| Arcari, A; Bernuzzi, P; Cabras, MG; Carli, G; Chiappella, A; Cox, MC; Gentile, M; Ghio, F; Ilariucci, F; Marasca, R; Marino, D; Musto, P; Santagostino, A; Savini, P; Spina, M; Tani, M; Valenti, V; Vallisa, D; Zambello, R; Zanlari, L | 1 |
| Asch, AS; Deal, AM; Foster, MC; Grover, NS; Ivanova, A; Muss, HB; Olajide, O; Park, SI; Richards, KL; Shea, TC; Sobol, AL; Wall, JG | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
| Nagai, Y; Nagashima, K; Sugita, Y; Tanaka, H | 1 |
| Ogura, M | 1 |
| Gregory, SA; Rummel, MJ | 1 |
| Dietrich, S; Ho, A; Schmitt, T; Walter, E; Witzens-Harig, M | 1 |
7 review(s) available for bendamustine hydrochloride and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Treatment Outcome | 2022 |
Treatment strategies for patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine | 2022 |
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Topics: Antigens, CD19; Bendamustine Hydrochloride; Cost-Effectiveness Analysis; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Diffuse large B-cell lymphoma: new targets and novel therapies.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Development; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Rituximab | 2021 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Gene Targeting; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Prednisone; Prognosis; Purine Nucleosides; Pyrimidinones; Risk; Rituximab; Salvage Therapy; Sirolimus; Transplantation, Autologous; Vincristine | 2008 |
Bendamustine's emerging role in the management of lymphoid malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2011 |
12 trial(s) available for bendamustine hydrochloride and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult | 2022 |
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Circulating Tumor DNA; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab | 2022 |
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Rituximab | 2022 |
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Female; Humans; Immunoconjugates; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Progression-Free Survival; Survival Rate | 2020 |
Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Retrospective Studies; Rituximab | 2019 |
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Female; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pilot Projects; Rituximab; Salvage Therapy; Treatment Outcome; Young Adult | 2018 |
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Standard of Care; Vincristine | 2019 |
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation | 2013 |
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Incidence; Intention to Treat Analysis; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Patient Dropouts; Rituximab; Secondary Prevention; Survival Analysis; United States | 2014 |
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Rituximab; Survival Rate | 2014 |
Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2015 |
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Cause of Death; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Staging; Prognosis; Rituximab; Treatment Outcome | 2016 |
29 other study(ies) available for bendamustine hydrochloride and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Economic evaluation of polatuzumab-bendamustine-rituximab
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2021 |
Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2022 |
[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2022 |
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2022 |
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Oxaliplatin; Retrospective Studies; Rituximab; Treatment Outcome | 2022 |
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Topics: Bendamustine Hydrochloride; Cyclophosphamide; Cytokine Release Syndrome; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Receptors, Antigen, T-Cell | 2022 |
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Rituximab | 2022 |
United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD79 Antigens; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2022 |
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neurolymphomatosis; Rituximab | 2023 |
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Topics: Adult; Antigens, CD19; Bendamustine Hydrochloride; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen | 2023 |
[Autologous stem cell transplantation after pola-BR regimen as a salvage therapy in relapsed diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Salvage Therapy; Transplantation, Autologous | 2023 |
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Bendamustine Hydrochloride; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2; Vaccination | 2023 |
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large
Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab | 2023 |
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab | 2023 |
[Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma].
Topics: Aged; Bendamustine Hydrochloride; Female; Humans; Lymph Nodes; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2020 |
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Frail Elderly; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Progression-Free Survival; Rituximab | 2021 |
Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Staging; Prednisone; Remission Induction; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Bilateral primary adrenal lymphoma successfully treated with non-CHOP chemotherapy regimen.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Rituximab; Vomiting | 2018 |
Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2013 |
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Mice; Naphthoquinones; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Rituximab; Survivin; Xenograft Model Antitumor Assays | 2014 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; DNA Breaks, Double-Stranded; Gene Expression; Genes, p53; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Vorinostat | 2016 |
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Disease-Free Survival; Female; Follow-Up Studies; Humans; Italy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |
Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bendamustine Hydrochloride; Bone Marrow; Female; Humans; Japan; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Pancytopenia; Prednisolone; Rituximab; Treatment Outcome | 2016 |
Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2012 |